Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies.

Burghardt KJ, Seyoum B, Mallisho A, Burghardt PR, Kowluru RA, Yi Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:55-63. doi: 10.1016/j.pnpbp.2018.01.004. Epub 2018 Jan 8.

PMID:
29325867
2.

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.

Goldsmith P, Affinito J, McCue M, Tsai M, Roepcke S, Xie J, Gertsik L, Macek TA.

Drugs R D. 2017 Dec;17(4):631-643. doi: 10.1007/s40268-017-0214-8.

3.

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.

Freyberg Z, Aslanoglou D, Shah R, Ballon JS.

Front Neurosci. 2017 Jul 28;11:432. doi: 10.3389/fnins.2017.00432. eCollection 2017.

4.
5.

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.

Tsai M, Chrones L, Xie J, Gevorkyan H, Macek TA.

Psychopharmacology (Berl). 2016 Oct;233(21-22):3787-3795. Epub 2016 Aug 30.

6.

Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran.

Shakeri J, Karimi K, Farnia V, Golshani S, Alikhani M.

Oman Med J. 2016 Jul;31(4):270-5. doi: 10.5001/omj.2016.53.

7.

Microvascular dysfunction in schizophrenia: a case-control study.

Vetter MW, Martin BJ, Fung M, Pajevic M, Anderson TJ, Raedler TJ.

NPJ Schizophr. 2015 Jul 1;1:15023. doi: 10.1038/npjschz.2015.23. eCollection 2015.

8.

Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record.

Lui K, Randhawa G, Totten V, Smith AE, Raese J.

Prim Care Companion CNS Disord. 2016 Jan 28;18(1). doi: 10.4088/PCC.15m01849. eCollection 2016.

9.

Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review.

Mangurian C, Newcomer JW, Modlin C, Schillinger D.

J Gen Intern Med. 2016 Sep;31(9):1083-91. doi: 10.1007/s11606-016-3712-4. Epub 2016 May 5. Review.

10.

Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.

Vincenzi B, Greene CM, Ulloa M, Parnarouskis L, Jackson JW, Henderson DC.

J Psychiatr Pract. 2016 May;22(3):175-82. doi: 10.1097/PRA.0000000000000149.

11.

Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.

Yu H, Wang L, Lv L, Ma C, Du B, Lu T, Jin C, Yan H, Yang Y, Li W, Ruan Y, Zhang H, Zhang H, Mi W, Mowry B, Ma W, Li K, Zhang D, Yue W.

Schizophr Bull. 2016 May;42(3):814-23. doi: 10.1093/schbul/sbv179. Epub 2015 Dec 9.

12.

Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.

Teff KL, Rickels K, Alshehabi E, Rickels MR.

J Clin Psychopharmacol. 2015 Oct;35(5):579-82. doi: 10.1097/JCP.0000000000000393.

13.

Dietary patterns and schizophrenia: a comparison with healthy controls.

Tsuruga K, Sugawara N, Sato Y, Saito M, Furukori H, Nakagami T, Nakamura K, Takahashi I, Nakaji S, Yasui-Furukori N.

Neuropsychiatr Dis Treat. 2015 Apr 22;11:1115-20. doi: 10.2147/NDT.S74760. eCollection 2015.

14.

Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics.

Kang SH, Lee JI.

Psychiatry Investig. 2015 Apr;12(2):242-8. doi: 10.4306/pi.2015.12.2.242. Epub 2015 Mar 18.

15.

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study.

Wani RA, Dar MA, Chandel RK, Rather YH, Haq I, Hussain A, Malla AA.

Neuropsychiatr Dis Treat. 2015 Mar 13;11:685-93. doi: 10.2147/NDT.S80925. eCollection 2015. Erratum in: Neuropsychiatr Dis Treat. 2015;11:863.

16.

Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.

Flory J, Haynes K, Leonard CE, Hennessy S.

Br J Clin Pharmacol. 2015 Feb;79(2):330-6. doi: 10.1111/bcp.12506.

17.

A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.

Gilca M, Piriu G, Gaman L, Delia C, Iosif L, Atanasiu V, Stoian I.

Psychopharmacology (Berl). 2014 Dec;231(24):4703-10. doi: 10.1007/s00213-014-3624-0. Epub 2014 May 29.

18.

Effects of clozapine administration on body weight, glucose tolerance, blood glucose concentrations, plasma lipids, and insulin in male C57BL/6 mice: A parallel controlled study.

Yuan HY, Liang HX, Liang GR, Zhang GX, Li HD.

Curr Ther Res Clin Exp. 2008 Apr;69(2):142-9. doi: 10.1016/j.curtheres.2008.04.007.

19.

Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study.

Roussidis A, Kalkavoura C, Dimelis D, Theodorou A, Ioannidou I, Mellos E, Mylonaki T, Spyropoulou A, Yfantis A.

Ann Gen Psychiatry. 2013 Dec 20;12(1):42. doi: 10.1186/1744-859X-12-42.

20.

Abnormal screening for gestational diabetes, maternal mood disorder, and preterm birth.

Sit D, Luther J, Dills JL, Eng H, Wisniewski S, Wisner KL.

Bipolar Disord. 2014 May;16(3):308-17. doi: 10.1111/bdi.12129. Epub 2013 Oct 24.

Supplemental Content

Support Center